KalVista Pharmaceuticals (NASDAQ:KALV) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research note published on Monday,Benzinga reports.

Several other brokerages have also issued reports on KALV. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday. Needham & Company LLC reissued a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th.

KalVista Pharmaceuticals Stock Down 4.8 %

KalVista Pharmaceuticals stock opened at $9.34 on Monday. KalVista Pharmaceuticals has a 52-week low of $7.39 and a 52-week high of $16.88. The company has a market cap of $461.58 million, a P/E ratio of -2.57 and a beta of 0.85. The business has a 50-day simple moving average of $10.85 and a two-hundred day simple moving average of $11.81.

Insider Activity at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 8,077 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the sale, the insider now owns 94,199 shares in the company, valued at approximately $872,282.74. This trade represents a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Benjamin L. Palleiko sold 14,400 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $133,344.00. Following the sale, the chief executive officer now directly owns 266,598 shares in the company, valued at $2,468,697.48. This trade represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,291 shares of company stock worth $304,086. 10.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC bought a new position in shares of KalVista Pharmaceuticals during the 2nd quarter valued at about $25,000. China Universal Asset Management Co. Ltd. boosted its stake in KalVista Pharmaceuticals by 67.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after buying an additional 3,328 shares during the last quarter. Intech Investment Management LLC bought a new position in KalVista Pharmaceuticals during the third quarter valued at approximately $126,000. SG Americas Securities LLC purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter worth approximately $153,000. Finally, Quest Partners LLC purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter worth approximately $175,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).